IBB vs RSP
iShares Biotechnology ETF vs Invesco S&P 500 Equal Weight ETF
- • RSP has the lower expense ratio at 0.20% vs 0.44% for IBB.
- • RSP pays a higher dividend yield (1.51%).
Side-by-side metrics
| Metric | IBB | RSP |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.44% | 0.20% |
Dividend yield Trailing 12-month yield. | 0.22% | 1.51% |
AUM Assets under management — bigger funds are typically more liquid. | $9.09B | $93.66B |
YTD return | 16.44% | 11.67% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.69 | 0.85 |
P/E ratio | 24.79 | 22.17 |
Last price | $196.62 | $214.01 |
Inception | — | — |
Issuer | iShares | Invesco |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
RSP top holdings
| MRNA | Moderna Inc | 0.29% |
| GLW | Corning Inc | 0.29% |
| AMAT | Applied Materials Inc | 0.28% |
| KLAC | KLA Corp | 0.27% |
| TER | Teradyne Inc | 0.27% |
| SNDK | SanDisk Corp Ordinary Shares | 0.27% |
| GEV | GE Vernova Inc | 0.26% |
| LRCX | Lam Research Corp | 0.26% |
| TECH | Bio-Techne Corp | 0.26% |
| UAL | United Airlines Holdings Inc | 0.26% |
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About RSP
RSP (Invesco S&P 500 Equal Weight ETF) is S&P 500 with each stock equally weighted. Managed by Invesco, the fund carries $93.7B in assets under management, an expense ratio of 0.20%, a dividend yield of 1.51%. Its largest holding is Moderna Inc (MRNA), which represents 0.3% of the portfolio. Real Estate is the fund's largest sector exposure at 5.9%.